Reflections on Recent Clinical Trials in Patients With Heart Failure and Those With Reduced Ventricular Function

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 2, Issue 3, 1997, Pages 147-152

  Ogunyankin, Kofo ^a   Singh, Bramah N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84992861189     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424849700200301     Document Type: Editorial

References (28)

1. The Digitalis Investigation Group. The effect of digoxin on mortality in patients with heart failure. N Engl J Med 336: 525. 1997
2. Singh SN, Fletcher RD, Fisher SG, Singh BN, et al. for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 33: 77, 1995
3. Doral HC Nul DR, Grancelli HO, Perrone SV, et al. for Grupo de Estudio de la Sobrevida en la Insufficiencia Cardiaca en Argentina (GESICA). Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet 34: 493, 1994
4. Packer M., Colucci WS, Sackner-Bernstein JD, Liang CS, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 94: 2793, 1996
5. Colucci WS, Packer M., Bristow MR, Gilbert ME, et al. for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 14: 2800, 1996
6. Bristow MR Gilbert EM, Abraham NT, Adams KF, et al. for the Mocha Investigators. Carvedilol produces dose-related improvements in left ventricular functions and survival in subjects with chronic heart failure. Circulation 94: 2807, 1996
7. Gilbert EM Abraham NT, Olsen S., Hattler B., et al. Congestive hemodynamic left ventricular functional and anti-adrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94: 2817, 1996
8. Packer M., Bristow MR, Cohn J., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349, 1996
9. Australia/New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349: 375, 1997
10. Pitt B., Segal R., Martinez FA, Meurero G., et al. on behalf of ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure: evaluation of losartan in the elderly study, ELITE. Lancet 349: 742, 1997
11. Julian DG, Camm AJ, Franglin G., et al. for the European Myocardial Infarct Amiodarone Trial Investigators. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349: 667, 1997
12. Cairns JA, Connolly SJ, Roberts RJ, Gent M. for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 394: 675, 1997
13. Moss AJ, Hall J., Cannom DS, Daubert JP, et al. for the Multicenter Automatic Defibrillator Implantation Trial Investigators (MADIT). Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular tachycardia. N Engl J Med 335: 1933, 1996
14. Packer M., O'Connor CM, Ghali JK, et al. for the Prospective Randomized Amlodipine Survival Evaluation Study Group (PRAISE). Effect of amlodipine on morbidity and mortality in severe congestive heart failure. N Engl J Med 335: 1107, 1996
15. Packer M., Gheorghiade M., Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting—enzyme inhihitors: RADIANCE study. N Engl J Med 329: 1-7, 1993
16. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 22: 955, 1993
17. Deedwania PC, Singh BN, Fletcher R., Fisher S., et al. Amiodarone improves survival by restoring and maintaining sinus rhythm in patients with chronic atrial fibrillation, dilated cardiomyopathy, and congestive heart failure. Circulation 94: I-667; 3895, 1996
18. Massie BM, Fisher SG, Deedwania PC, Singh BN, Fletcher RD, Singh SN for the CHF-STAT Investigators. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 93: 2128. 1996
19. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study. Circulation 90: 1765, 1994
20. Yusuf S., Peto R. Lewis J., et al. Beta-blockade during myocardial infarction: an overview of randomized trials. Cardiovasc Dis 27: 335, 1985
21. Chadda K., Golstein S., Byington R., et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circ 73: 503, 1986
22. Waagstein F., Hjalmarson A., Varnaysclas E., Wallentin I. Effect of chronic-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 27: 1022, 1975
23. Krum, H., Sackner—Bernstein J., Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 92: 1499, 1995
24. Gilbert EM Abraham WT, Olsen S., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94: 2817, 1996
25. Singh BN Expanding indications for the use of class III agents in patients in high risk for sudden death. J Cardiovasc Electrophysiol 6: 887, 1995
26. Saksena S., Giorgberidze I. MADIT provides the basis for developing therapeutic strategy for patients with severel depressed ventricular ejection fraction with nonsustained ventricular tachycardia: protagonist view. J Cardiovasc Pharmacol Therapeut 2: 229, 1997
27. Epstein A. MADIT does not provide the basis for devloping therapeutic strategy for patients with severely depressed ventricular function with nonsustained ventricular tachycardia. J Cardiovasc Pharamcol Therapeut 2: 234, 1997
28. Wilber DJ, Olshansky B., Moran JF Electrophysiological testing and nonsustained ventricular tachycardia: use and limitation in patients with coronary artery disease and impaired ventricular function. Circulation 82: 350, 1990